| Metric | Value (₹ Cr) |
|---|---|
| Revenue | 180.03 |
| Total Income | 183.44 |
| Expenditure | 145.90 |
| PBT | 29.12 |
| Net Profit | 22.13 |
| OPM | 17.41% |
| NPM | 12.06% |
| EPS | 13.38 |
RPG Life Sciences Q3 FY26: Revenue up by 4.2% Y-o-Y and EBITDA margin at 24.0%
27 Jan 2026 · 27 Jan, 8:10 pm
Summary
RPG Life Sciences Limited has announced its financial results for the third quarter ended 31 December, 2025. The company recorded a 4.2% Y-o-Y increase in revenue and a healthy EBITDA margin of 24.0%. The Domestic Formulations business delivered growth ahead of the Indian Pharmaceutical Market, recording a growth of 11.8% in 9M FY26 compared to the IPM growth of 8.2%.
Key Highlights
- 1
Q-o-Q Revenue from operations Q3 FY26 Highlights Rs. 180.0 crores vs. Rs. 181.7 crores
- 2
Y-o-Y Revenue from operations Q3 FY26 Highlights Rs. 180.0 crores vs. Rs. 172.7 crores
- 3
9M FY26 Highlights Rs. 530.6 crores vs. Rs. 510.3 crores
- 4
RPG Life Sciences recorded a 4.2% Y-o-Y increase in revenue
- 5
Healthy EBITDA margin of 24.0%
- 6
Domestic Formulations business delivered growth ahead of the Indian Pharmaceutical Market, recording a growth of 11.8% in 9M FY26 compared to the IPM growth of 8.2%
Management Comments
Mr. Ashok Nair
Q3 reflects continued traction across our core businesses supported by disciplined execution and deliberate portfolio actions. Our Domestic Formulations business delivered growth ahead of the Indian Pharmaceutical Market, recording a growth of 11.8% in 9M FY26 compared to the IPM growth of 8.2%, driven by strong brand performance, improved field effectiveness, and sharper customer engagement. Our approach remains firmly rooted in quality and improving patient outcomes.
Informational and educational content only. Not investment advice.